Skip to main content
OpenTrials
Completed

NCT Number: NCT07755475

A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Function and Energy Levels

This study evaluates the effects of Artah's Cellular Hydration electrolyte supplement on cognitive function and energy levels in healthy adults aged 25-60 who experience mild to moderate fatigue, brain fog, or related symptoms. The trial is a single-arm, unblinded, virtual study in which all 50 participants will use the test product daily for 4 weeks.

Participants will complete self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4, and will undergo cognitive battery testing at Baseline and Week 4. The primary endpoint is change in cognitive performance scores as measured by a standardized cognitive battery. Secondary endpoints include participants' self-reported perceptions of mental clarity, alertness, mood, physical performance, overall energy levels, and frequency of food cravings.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Function Behavior Behavioral Symptoms Brain Fog Energy Levels Fatigue Food Cravings Mental Clarity Mental Fatigue Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

25 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89101, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female.
  • Be aged 25-60.
  • Anyone currently experiencing mild to moderate issues with at least three of the following: low energy or fatigue
  • difficulty concentrating or low mental sharpness
  • experiences of brain fog or lack of mental clarity
  • feeling of low productivity
  • muscle weakness
  • unwanted food cravings.
  • Undertakes moderate to high-intensity exercise such as jogging/running and/or heavy resistance training at least three times per week.
  • Willing to refrain from taking any products, medications, or supplements that target energy, cognition, or physical performance during the test period.
  • Anyone with a BMI 18.5 to 30.
  • Anyone who has access to a device (e.g., smartphone, laptop, computer) for reliable internet.
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Anyone willing to maintain a consistent diet and physical activity throughout study duration.

Exclusion criteria

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone suffering from gastrointestinal disorders including but not limited to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and celiac disease.
  • Anyone suffering from hyperkalemia (high potassium), liver disease, or kidney disease.
  • Anyone taking ACE inhibitors or potassium-sparing diuretics, examples include: Spironolactone (Aldactone), Eplerenone (Inspra), Amiloride (Midamor), Triamterene (Maxzide), Lisinopril (Zestril, Prinivil), Enalapril (Vasotec), Ramipril (Altace), Benazepril (Lotensin), Quinapril (Accupril), Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), Lithium carbonate (Lithobid, Eskalith).
  • Anyone taking antibiotics.
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
  • Anyone unwilling to follow the study protocol.
  • Anyone with a history of substance abuse.
  • Anyone who is a shift worker with an irregular sleep-wake cycle.
  • Anyone who drinks heavily (8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
  • Anyone who is currently a smoker or has been a smoker in the past 3 months.
  • Currently partaking in another research study, or planning to at any point during this study's duration.

Treatment and study plan

Cellular Hydration Supplement

Dietary Supplement

All 50 participants receive the Artah Cellular Hydration electrolyte supplement taken twice daily (once in the morning before the first meal and once in the afternoon after lunch or before evening exercise) as one teaspoon (approximately 7 g) stirred into 750 ml of water for 4 weeks.

Primary outcomes

  1. Change in Cognitive Battery Test Score (Polygons)

    Time frame: Baseline and Week 4

    Change in processing speed and information sorting ability assessed via the Polygons timed cognitive battery subtest

  2. Change in Cognitive Battery Test Score (Double Trouble)

    Time frame: Baseline and Week 4

    Change in selective attention and processing speed assessed via the Double Trouble timed cognitive battery subtest (Stroop-based)

  3. Change in Cognitive Battery Test Score (Feature Match)

    Time frame: Baseline and Week 4

    Change in focus and processing speed assessed via the Feature Match timed cognitive battery subtest

  4. Change in Cognitive Battery Test Score (Paired Associates)

    Time frame: Baseline and Week 4

    Change in memory recall assessed via the Paired Associates performance-based cognitive battery subtest

  5. Change in Cognitive Battery Test Score (Digit Span)

    Time frame: Baseline and Week 4

    Change in short-term memory and cognitive flexibility assessed via the Digit Span performance-based cognitive battery subtest

  6. Change in Cognitive Battery Test Score (Spatial Planning)

    Time frame: Baseline and Week 4

    Change in executive function and logical decision-making assessed via the Spatial Planning timed cognitive battery subtest

Secondary outcomes

  1. Change in Self-Reported Mental Clarity and Focus

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

    Assessed via self-reported questionnaire

  2. Change in Self-Reported Alertness

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

    Assessed via self-reported questionnaire

  3. Change in Self-Reported Mood

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

    Assessed via self-reported questionnaire

  4. Change in Self-Reported Physical Performance

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

    Assessed via self-reported questionnaire

  5. Change in Self-Reported Overall Energy Levels

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

    Assessed via self-reported questionnaire

  6. Change in Self-Reported Frequency of Food Cravings

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

    Assessed via self-reported questionnaire

Sponsors and collaborators

Lead sponsor

Artah Nutrition Limited

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 10, 2026
Registry last updated
Aug 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.